Interactions between rabeprazole and Invirase (saquinavir)
saquinavir and rabeprazole (Moderate Drug-Drug)
MONITOR: The concomitant administration of omeprazole and saquinavir/ritonavir may significantly increase exposure to saquinavir. When omeprazole 40 mg once daily and saquinavir/ritonavir 1000/100 mg twice daily were administered to healthy subjects (n=18), the steady-state area under the concentration-time curve (AUC) and maximum plasma concentrations (Cmax) of saquinavir were increased by an average of 82 % (range, 37% to 234%) and 75 % (range, 31% to 234%), respectively, compared to saquinavir/ritonavir. Ritonavir concentrations were not changed significantly. The mechanism is unknown.
MANAGEMENT: Clinical and laboratory monitoring for saquinavir toxicity is recommended during concurrent use of a proton pump inhibitor.
